Market Cap 625.30M
Revenue (ttm) 197.61M
Net Income (ttm) -130.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -65.95%
Debt to Equity Ratio 2.27
Volume 28,721
Avg Vol 92,062
Day's Range N/A - N/A
Shares Out 94.89M
Stochastic %K 10%
Beta 1.67
Analysts Strong Sell
Price Target $12.20

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-a...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 2 28 07 37 10
Fax: 33 2 28 07 37 11
Website: valneva.com
Address:
6 rue Alain Bombard, Saint-Herblain, France
Latest News on VALN
No data available.